Compugen Ltd. Could Turn A Profit If Co. Can Secure More Deals Like Bayer AG's Oncology Deal

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Israel's Compugen (CGEN.TA), which is trying to develop commercial drugs using computer models, says it could turn a profit if it can secure two or three more deals like its recent partnership with Bayer (BAYGn.DE) in immuno-oncology. The company, which does not yet have a drug on the market, agreed in August to hand over the rights to two proteins known as immune checkpoint inhibitors to the German drug firm for antibody-based cancer immunotherapies. The deal calls for Compugen to receive $10 million up front, $30 million in milestone payments for joint pre-clinical work and more than $500 million for milestones beyond the pre-clinical stage.

Help employers find you! Check out all the jobs and post your resume.

Back to news